355 related articles for article (PubMed ID: 22685175)
1. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
[TBL] [Abstract][Full Text] [Related]
2. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.
Francis OL; Milford TA; Martinez SR; Baez I; Coats JS; Mayagoitia K; Concepcion KR; Ginelli E; Beldiman C; Benitez A; Weldon AJ; Arogyaswamy K; Shiraz P; Fisher R; Morris CL; Zhang XB; Filippov V; Van Handel B; Ge Z; Song C; Dovat S; Su RJ; Payne KJ
Haematologica; 2016 Apr; 101(4):417-26. PubMed ID: 26611474
[TBL] [Abstract][Full Text] [Related]
3. TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia.
Alkashgari HR; Ruiz-Jimenez C; Stoian C; Coats JS; Baez I; Chirshev E; Martinez SR; Dovat S; Francis-Boyle OL; Casiano CA; Payne KJ
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613920
[TBL] [Abstract][Full Text] [Related]
4. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
5. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
[TBL] [Abstract][Full Text] [Related]
6. Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.
Jiang M; Zou X; Lu L
Oncol Rep; 2019 Feb; 41(2):885-894. PubMed ID: 30535452
[TBL] [Abstract][Full Text] [Related]
7. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.
van Bodegom D; Zhong J; Kopp N; Dutta C; Kim MS; Bird L; Weigert O; Tyner J; Pandey A; Yoda A; Weinstock DM
Blood; 2012 Oct; 120(14):2853-63. PubMed ID: 22915648
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
Savino AM; Sarno J; Trentin L; Vieri M; Fazio G; Bardini M; Bugarin C; Fossati G; Davis KL; Gaipa G; Izraeli S; Meyer LH; Nolan GP; Biondi A; Te Kronnie G; Palmi C; Cazzaniga G
Leukemia; 2017 Nov; 31(11):2365-2375. PubMed ID: 28331226
[TBL] [Abstract][Full Text] [Related]
9. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
10. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.
Brown VI; Hulitt J; Fish J; Sheen C; Bruno M; Xu Q; Carroll M; Fang J; Teachey D; Grupp SA
Cancer Res; 2007 Oct; 67(20):9963-70. PubMed ID: 17942929
[TBL] [Abstract][Full Text] [Related]
11. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
[TBL] [Abstract][Full Text] [Related]
12. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
13. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
14. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
15. A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB
Int J Biol Macromol; 2021 Nov; 190():214-223. PubMed ID: 34481852
[TBL] [Abstract][Full Text] [Related]
16. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
[TBL] [Abstract][Full Text] [Related]
17. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.
Hurtz C; Wertheim GB; Loftus JP; Blumenthal D; Lehman A; Li Y; Bagashev A; Manning B; Cummins KD; Burkhardt JK; Perl AE; Carroll M; Tasian SK
J Clin Invest; 2020 Jul; 130(7):3637-3653. PubMed ID: 32191635
[TBL] [Abstract][Full Text] [Related]
18. CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.
Moreno Lorenzana D; Juárez Velázquez MDR; Reyes León A; Martínez Anaya D; Hernández Monterde A; Salas Labadía C; Navarrete Meneses MDP; Zapata Tarrés M; Juárez Villegas L; Jarquín Ramírez B; Cárdenas Cardós R; Herrera Almanza M; Paredes Aguilera R; Pérez Vera P
J Pathol Clin Res; 2021 Jul; 7(4):410-421. PubMed ID: 33890726
[TBL] [Abstract][Full Text] [Related]
19. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
20. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
Tasian SK; Loh ML
Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
